High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-230X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study ; volume:21 ; number:1 ; day:18 ; month:2 ; year:2021 ; pages:1-8 ; date:12.2021
BMC gastroenterology ; 21, Heft 1 (18.2.2021), 1-8, 12.2021
- Creator
-
Wilson, Aze
Choi, Bethany
Sey, Michael
Ponich, Terry
Beaton, Melanie
Kim, Richard B.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12876-021-01650-7
- URN
-
urn:nbn:de:101:1-2021040719082012213667
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wilson, Aze
- Choi, Bethany
- Sey, Michael
- Ponich, Terry
- Beaton, Melanie
- Kim, Richard B.
- SpringerLink (Online service)
Other Objects (12)
Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis
Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis
Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial
Histologic improvement predicts endoscopic remission in patients with ulcerative colitis
Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab
Sustained rheumatoid arthritis remission is uncommon in clinical practice
Patient’s perspective of sustained remission in rheumatoid arthritis
Defining and characterizing sustained remission in patients with rheumatoid arthritis
Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease
Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study
Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis
Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis
Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial
Histologic improvement predicts endoscopic remission in patients with ulcerative colitis
Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab
Sustained rheumatoid arthritis remission is uncommon in clinical practice
Patient’s perspective of sustained remission in rheumatoid arthritis
Defining and characterizing sustained remission in patients with rheumatoid arthritis
Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease
Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study
Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis
Sustained clinical remission under infliximab/rituximab combination therapy in a patient with granulomatosis with polyangiitis
Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial
Histologic improvement predicts endoscopic remission in patients with ulcerative colitis
Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab
Sustained rheumatoid arthritis remission is uncommon in clinical practice
Patient’s perspective of sustained remission in rheumatoid arthritis
Defining and characterizing sustained remission in patients with rheumatoid arthritis
Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients
Ustekinumab trough levels predicting laboratory and endoscopic remission in patients with Crohn’s disease